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 Irritable bowel syndrome (IBS) is a common and poten-
tially disabling, though nonfatal, medical disorder that 
can affect up to 20% of the population. It is the most com-
mon functional gastrointestinal disorder referred to gas-
troenterologists ( 1 ). Although it has evolved over the years 
in terms of nomenclature ( 2, 3 ), classifi cation ( 4–6 ), and 
appreciation of its frequency ( 7 ), a poor understanding of 
disease pathophysiology has remained a constant. Accord-
ing to the Rome III criteria, a symptom-based classifi cation 
system, the disease-defi ning symptom profi le encompasses 
abdominal pain and an altered bowel habit, with disten-
sion, bloating, and a variety of disturbances in defecatory 
function being additional features ( 8 ). 
 The disorder is increasingly viewed as a disorder of the 
brain-gut axis, a construct describing a bidirectional inter-
action between the gastrointestinal tract (GIT), incorpo-
rating the intestinal epithelial barrier, the mucosa-associated 
lymphoid tissue (MALT), gut muscle and the enteric ner-
vous system (ENS), and the central nervous system (CNS) 
( 9, 10 ). Most recently, the proposal that low-grade infl am-
mation, as evidenced by the release of mast cell mediators 
and activation of lymphocytes in the colo-rectal mucosa 
and by the detection of elevated levels of pro-infl ammatory 
cytokines in serum ( 8, 11–13 ), has provided a new dimen-
sion to this paradigm. The source of this low-grade infl am-
mation, or immune activation, whether luminal or central, 
has remained elusive. Polyunsaturated fatty acids (PUFA) 
and their metabolites have been shown to infl uence in-
fl ammatory processes ( 14 ). Moreover, a pro-infl ammatory 
PUFA profi le has recently been reported in the maternal 
separation rodent model, an animal model of IBS ( 15 ). 
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attended gastroenterology clinics at Cork University Hospital or 
had responded to direct advertisement on the university campus 
or local newspaper regarding participation in IBS research. Indi-
viduals aged between 18 and 65 years who satisfi ed Rome II crite-
ria for IBS and in whom organic gastrointestinal diseases and 
clinically signifi cant systemic diseases had been excluded were 
considered for inclusion in the study. Pregnant women, individu-
als with known lactose intolerance or immunodefi ciency, or indi-
viduals who had any recent transient illness (i.e., within 2 weeks 
of participation in the study), such as viral illnesses or chest infec-
tions, were excluded. 
 Trial protocol 
 A total of 67 subjects, 41 patients with IBS and 26 healthy, sex-
matched controls of comparable age and BMI, gave fully informed 
consent to take part in this study, which had local ethics committee 
approval. Each potentially eligible patient was evaluated by a re-
view of clinical history, performance of a physical examination, 
and measurement of full blood count and serum biochemistry, 
with any clinically signifi cant abnormalities leading to exclusion. 
The age (mean ± SD) of the patients was 45 ± 11.74 years, and the 
age of the comparison group was 39.04 ± 12.78. All patients and 
healthy comparison subjects were drug free, including anti-infl am-
matory medications. The study was powered to detect differences 
in fatty acid concentrations at the  P < 0.05 level between controls 
and IBS patients but not within patient subgroups. 
 Assessments 
 On arrival at the clinical investigation laboratory at 08.30 h, 
each subject completed the self report patient health question-
naire (PHQ) to assess the presence of major depression. This is a 
reliable and valid instrument that was developed as a diagnostic 
tool to be used in primary care ( 28 ). It tests for the presence of 
major depression using diagnostic criteria from the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition (DSM-
IV). The responses on the depression subscale of the question-
naire can also be used as a dimensional tool to rate the severity of 
depression ( 29 ). In addition to the PHQ, clinical severity of IBS 
was evaluated using self report ordinal scales in accordance with 
a previously published method ( 30, 31 ). This involved subjects 
rating the severity of their IBS symptoms on a four-point ordinal 
scale (0-–3) with regard to each abdominal complaint, interfer-
ence with daily activities, and avoidance behavior as a result of 
complaints. A summarizing severity score for each patient was 
determined by taking the sum of the individual scores. 
 Sample collection 
 Whole blood was collected at 09.00 h in tubes that contained 
ethylenediametetraacetic acid (EDTA). Samples were centri-
fuged immediately and the plasma frozen at   80°C until ready 
for analysis. Serum, where applicable, was generated similarly ex-
cept that the collection tubes did not contain any anticoagulant. 
 Reagents 
 HPLC-grade methanol and chloroform were obtained from 
Alkem/Reagecon (Cork, Ireland). All other reagents were ob-
tained from Sigma (Germany) unless otherwise stated. 
 Fatty acid analysis 
 Lipids from 1 ml of blood plasma were extracted with 25 ml of 
chloroform:methanol 2:1 (v/v) containing 5 ppm butylated hy-
droxytoluene as an antioxidant ( 32 ), and the solvent was re-
moved via gentle evaporation at 45°C under nitrogen gas. 
Phospholipids were then separated by solid phase extraction us-
ing 500 mg NH2 phase columns (Phenomenex, UK) as described 
However, it has not been extensively studied in this regard 
in the clinical setting even though it may provide some 
new insights into disease pathophysiology. 
 The fatty acid composition of the body is largely deter-
mined by dietary intake ( 16 ). Western society has a high 
ratio of   -6 PUFA compared with   -3 PUFA largely due to a 
high consumption of   -6–rich vegetable oils in comparison 
to a low consumption of   -3–rich foods such as oily fi sh 
( 17 ). The dietary dominance of the   -6 fatty acids favors the 
elaboration of pro-infl ammatory mediators produced along 
  -6 metabolic pathways over less infl ammatory   -3 pathway 
metabolites. This imbalance, with a shift in a pro-infl amma-
tory direction, has been implicated in a number of diseases, 
including cardiovascular disease ( 18 ), depression ( 19, 20 ) 
and a variety of infl ammatory states ( 21 ). Moreover, the bio-
logical signifi cance of this ratio in these disease states is con-
fi rmed by studies showing that dietary manipulations aimed 
at reducing   -6 dominance can result in favorable disease 
outcomes with, for example, a reduction of the   -6:  -3 ratio 
to less than 4:1 being credited with reduced mortality in 
cardiovascular disease ( 17 ). This focus on the pro-infl am-
matory potential of the   -6 fatty acids has, in particular, 
been directed toward the role of arachidonic acid (AA) and 
its metabolites as infl ammatory mediators ( 22 ). 
 AA is a 20-carbon PUFA that is derived from   -6 fatty ac-
ids and subsequently enters a biochemical cascade to give 
rise to potent immunomodulatory eicosanoids including 
prostaglandin E 2 (PGE 2 ) and leukotriene B 4 (LTB 4 ) ( 23 ). 
Given the dietary factors outlined above, AA is the major 
substrate for synthesis of these eicosanoids, produced by the 
action of cylcooxygenase and lipoxygenase enzymes, respec-
tively, in Western societies ( 22 ). These prostaglandins and 
leukotrienes can be biologically active even at very low con-
centrations, and thus, minor alterations in AA status can 
induce profound downstream consequences ( 23 ). Interest-
ingly, PGE 2 has been shown to induce IL-6 synthesis in mac-
rophages ( 24 ). Elevated IL-6 levels have, to date, represented 
one of the most robust fi ndings supportive of immune acti-
vation in IBS ( 11, 25, 26 ). Despite the importance of the AA 
cascade, the limited data available on PUFA in IBS have not 
focused on either the parent molecule or the immunomod-
ulatory metabolites produced along the pathway ( 27 ). 
 In this study we hypothesized that the infl ammatory sig-
nature in IBS is derived from an increased dominance of 
  -6 PUFA over their   -3 counterparts, leading to an in-
creased input to the AA cascade. To test this theory, we mea-
sured the plasma PUFA profi le in IBS patients and healthy 
controls and also examined possible downstream altera-
tions in eicosanoid production. The analysis endpoints for 
this study were total plasma   -6 content, total plasma   -3 
content, the   -6:  -3 ratio, plasma AA concentrations, serum 
PGE 2 concentrations, and serum LTB 4 concentrations. 
 MATERIALS AND METHODS 
 Subjects 
 Female patients were recruited from a university database of 
IBS patients. The database consisted of people who had either 
1188 Journal of Lipid Research Volume 51, 2010
  -3 levels.  Plasma total   -3 content was signifi cantly el-
evated in the IBS cohort compared with controls (4.94 ± 
0.33 versus 3.88 ± 0.30 g/100 g FAME; t = 2.21, df = 65,  P = 
0.03). An ANOVA analysis did not reveal any differences 
between disease subtypes or status ( Table 1 ). 
  -6:  -3 ratio.  There was a trend toward a decreased 
  -6:  -3 ratio in the IBS patients relative to control subjects 
(8.03 ± 0.64 versus 10.25 ± 1.17; t = 1.81, df = 65,  P = 0.07). 
An ANOVA analysis did not highlight any differences 
between disease subtypes or disease status ( Table 1 ). 
 Arachidonic acid levels 
 Plasma AA concentrations were signifi cantly elevated in 
IBS patients compared with controls (8.52 ± 0.26 versus 
7.53 ± 0.37 g/100 g FAME; t = 2.22, df = 65,  P = 0.029) 
( Fig. 1A ). An ANOVA analysis revealed that the increase 
observed could not be assigned to a particular disease sub-
type ( Table 1 ). An ANOVA analysis followed by a Dunnets 
multiple comparison posthoc test revealed that the cur-
rently active subgroup had signifi cantly elevated plasma 
AA concentrations compared with control levels (9.09 ± 
0.54 versus 7.53 ± 0.37 g/100 g FAME; q = 2.86, df = [3, 
63],  P < 0.05) ( Fig. 1B ). An ANCOVA analysis revealed no 
infl uence of smoking habits on these results (F = 1.60, df = 
[1, 63],  P = 0.21). 
 Eicosanoid analysis 
 PGE 2 serum concentrations were signifi cantly elevated 
in the IBS group compared with controls (1490 ± 142.3 
versus 934.2 ± 145.7 pg/ml; t = 2.69, df = 42,  P = 0.01) ( Fig. 
2A ). An ANOVA analysis followed by Dunnets multiple 
comparison posthoc test revealed that the D-IBS subtype 
had signifi cantly elevated PGE 2 levels compared with con-
trols (1835 ± 362.8 versus 934.2 ± 145.7 pg/ml; q = 2.663, 
df = [3, 40],  P < 0.05) ( Fig. 2B ). A similar analysis across 
disease status subgroups revealed a nonsignifi cant trend 
toward increased PGE 2 levels in all categories ( Table 1 ). 
Technical reasons prevented the measurement of LTB 4 
levels in two of the control samples and four of the patient 
samples. LTB 4 serum concentrations were signifi cantly el-
evated in the IBS cohort compared with controls (332.2 ± 
31.33 versus 226.0 ± 36.70 pg/ml; t = 2.21, df = 35,  P = 
0.03) ( Fig. 3 ). An ANOVA analysis did not reveal any 
differences between IBS subtypes or status ( Table 1 ). An 
ANCOVA analysis revealed no infl uence of smoking habits 
(PGE 2 : F = 0.85, df = [1, 40],  P = 0.36; LTB 4 : F = 0.66, df = 
[1, 33],  P = 0.42) or age (PGE 2 : F = 0.01, df = [1, 40],  P = 
0.9; LTB 4 : F = 0.66, df = [1, 33],  P = 0.42) on these results. 
 Correlation analysis 
 There was no correlation between IBS symptom severity 
and plasma AA levels (Pearson product moment correla-
tion,  r = 0.16, df = 39,  P = 0.33). Neither was there a corre-
lation between depression scores and plasma AA levels 
(Pearson product moment correlation,  r = 0.17, df = 39, 
 P = 0.30). Plasma AA levels were nonsignifi cantly elevated 
regardless of whether they are classifi ed according to IBS 
severity (8.49 ± 0.61 g/100 g FAME in the mild group, 
previously ( 33 ). Phospholipids were transesterifi ed as previously 
described ( 34 ), extracted with 4 mls of hexane and an aliquot 
taken for gas chromatography (GC) analysis. 
 Fatty acids were quantifi ed as fatty acid methyl esters (FAME) 
by GC analysis using a Varian 3400 gas liquid chromatograph 
(Varian 3400 capillary GC, Varian, Walnut Creek, CA) fi tted with 
a fl ame ionization detector. The results were expressed as a per-
centage of FAME (%, g/100 g FAME). Separation of the FAME 
was performed on a Chrompack CP Sil 88 column (Chrompack, 
Middlelburg, The Netherlands) 100 m × 0.25mm ID × 20   m fi lm 
thickness). Helium was used as a carrier gas at a pressure of 33.7 
psi. The injector temperature was 225°C isothermal with a hold 
time of 5 min and the detector temperature was 250°C. The col-
umn temperature was programmed from an initial temperature 
of 80°C to a fi nal temperature of 200°C, with an initial delay of 8 
min (hold time), at a rate of 8.5°C/min during each analysis. The 
column was held at the fi nal temperature of 200°C for 7 min (fi -
nal hold time). Collected data were recorded and analyzed on a 
Minichrom PC system (VG Data Systems, Manchester, UK). Fatty 
acids were identifi ed based on the retention time of reference 
standards (Sigma). 
 Eicosanoid analysis 
 PGE 2 and LTB 4 were measured in serum from a reduced subject 
group of the trial subjects outlined above. From 25 of the patient 
group (47 ± 10.63 years) and 19 of the control group (36.21 ± 
11.87 years), serum samples in addition to the plasma samples 
were prepared. Separate Assay Designs EIA assay kits (Cambridge 
Biosciences, UK) were used to measure the analytes, and the assays 
were performed as per the manufacturer’s instructions. 
 Data analysis 
 Data were expressed as mean values ± SEM. Data were analyzed 
by Student-test, one way ANOVA, ANCOVA, and by Dunnets mul-
tiple comparison posthoc tests as appropriate. Correlations were 
assessed according to the Pearson product moment correlation. 
 RESULTS 
 Subject characteristics 
 DSM-IV major depression was comorbid in 41% (17 out 
of 41) of IBS patients. None of the control group (n = 26) 
met criteria for current depression. Twenty-two per cent 
(9 out of 41) of patients rated their IBS symptoms as mild 
(a sum score of 3 or less on the severity scale); 41% (17 out 
of 41) reported symptoms of moderate severity; and 37% 
(15 out of 41) reported symptoms which were severe in 
nature (i.e., a score of 6 or greater on the severity scale). 
Twelve of the IBS cohort were classifi ed as having diarrhea-
predominant IBS (D-IBS), 9 as constipation-predominant 
(C-IBS), and 20 had an alternating bowel habit (A-IBS). In 
addition, 17 of the IBS group had currently active symp-
toms (CA), 17 were categorized as recently active (RA), 
and 7 were in a quiescent disease phase (Q). 
 PUFA profi le in IBS 
  -6 levels.  There was no difference between plasma to-
tal   -6 content in IBS compared with controls (32.76 ± 
0.48 versus 32.59 ± 0.61 g/100 g fatty acid methyl esters 
(FAME); t = 0.22, df = 65,  P = 0.83). An ANOVA did not 
reveal any differences between disease subtype or disease 
status ( Table 1 ). 
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The principal fi nding in this study is that plasma AA con-
centrations were signifi cantly elevated in the IBS cohort 
compared with controls. Although the study was not pow-
ered to detect IBS subgroup differences, an analysis of the 
data according to disease status revealed that the data was 
robust enough to indicate that it was the currently active 
IBS cohort that made the largest contribution to the ele-
vated plasma AA concentrations. Although a further analy-
sis according to disease subtype (C-IBS, A-IBS, or D-IBS) 
did not yield any statistically signifi cant results, there ap-
peared to be a uniform increase across all disease subtypes. 
Interestingly, a previous study that examined plasma fatty 
acid profi les in a mixed gender IBS cohort did not report 
any alterations ( 27 ). However, although that study did re-
port AA concentrations, it was not one of its statistical end-
point measures nor did it examine the infl ammatory 
mediators produced along the AA cascade. Moreover, it 
8.49 ± 0.43 in the moderate group, and 8.57 ± 0.63 in 
the severe group; F = 1.60, df = [3, 63],  P = 0.20) ( Fig. 4A ) 
or ± depressive comorbidity (8.78 ± 0.42 in the depressed 
subgroup and 8.33 ± 0.34 in the nondepressed subgroup; 
F = 2.78, df = [2, 64],  P = 0.07) ( Fig. 4B ). Additional statis-
tical analysis revealed no correlation between depression 
scores and either serum PGE 2 or LTB 4 concentrations. 
Nor was there a correlation between IBS symptom severity 
and serum PGE 2 or LTB 4 concentrations (unpublished 
observations). 
 DISCUSSION 
 Here we show, what is to our knowledge, the fi rst dem-
onstration of altered circulating PUFA metabolites in IBS. 
 TABLE 1. PUFA concentrations (g/100 g FAME),   -6:  -3 ratio, and eicosanoid concentrations (pg/ml) in IBS 
according to disease subtype and status.  
Disease Subtype Disease Status
Parameter D-IBS C-IBS A-IBS F, (df),  P CA RA Q F, (df),  P 
Total   -6 33.16 ± 0.86 32.39 ± 0.94 32.69 ± 0.76 0.13, (3,63), 0.95 32.47 ± 0.49 32.05 ± 0.87 35.19 ± 1.19 1.88, (3,63), 0.14
Total   -3 4.49 ± 0.30 5.36 ± 0.78 5.02 ± 0.56 1.98, (3,63), 0.13 5.04 ± 0.43 5.20 ± 0.66 4.07 ± 0.38 2.22, (3,63), 0.09
  -6:  -3 7.89 ± 0.71 7.06 ± 1.56 8.27 ± 1.07 1.10, (3,63), 0.36 7.51 ± 0.88 8.81 ± 1.23 9.34 ± 0.94 1.24, (3,63), 0.30
AA 8.39 ± 0.41 8.05 ± 0.54 8.81 ± 0.42 2.03, (3,63), 0.12 9.09 ± 0.54 7.90 ± 0.60 8.63 ± 0.54 3.02, (3,63), 0.04 a 
PGE2 1835 ± 362.8 1115 ± 202.4 1500 ± 187.5 3.42, (3, 40), 0.03 a 1531 ± 364 1431 ± 142.6 1655 ± 527.6 2.41 (3, 40), 0.08
LTB4 339 ± 83.57 331.2 ± 66.57 331 ± 31.33 1.53, (3, 33), 0.22 361 ± 78.51 319.7 ± 38.34 324.3 ± 65.99 1.65 (3, 33), 0.2
 a  P < 0.05, one way ANOVA.
Abbreviations: AA, arachidonic acid; A-IBS, alternating IBS; C-IBS, constipation-predominant IBS; CA, currently active; D-IBS, diarrhea-
predominant IBS; FAME, fatty acid methyl esters; LTB 4 , leukotriene B 4 ; PGE 2 , prostaglandin E 2 ; PUFA, polyunsaturated fatty acid; Q, quiescent; RA, 
recently active.
 Fig.  1. Arachidonic acid levels (g/100 g FAME) in healthy female 
controls and female IBS patients. (1A) Elevation in AA levels in IBS 
patients (n = 41) compared with control levels (n = 26) (* P < 0.05, 
 t -test). (1B) AA levels in IBS patients according to disease status 
showing elevated AA levels in the currently active subdivision com-
pared with control values (* P < 0.05, control versus currently ac-
tive, ANOVA + Dunnetts posthoc test). AA, arachidonic acid; CA, 
currently active; FAME, fatty acid methyl esters; IBS, irritable bowel 
syndrome; RA, recently active; Q, quiescent. 
 Fig.  2. Serum PGE 2 levels (pg/ml) in healthy female controls and 
female IBS patients. (2A) Elevation in PGE 2 levels in IBS patients 
(n = 25) compared with control levels (n = 19) ( P < 0.05,  t -test). (2B) 
Elevation in PGE 2 levels in IBS patients categorized according to dis-
ease subtype compared with control levels (* P < 0.05, control versus 
D-IBS, ANOVA + Dunnetts). A-IBS, alternating IBS; C-IBS, constipa-
tion-predominant IBS; D-IBS, diarrhea-predominant IBS; IBS, irri-
table bowel syndrome; PGE 2 , prostaglandin E 2 . 
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contribution to the altered AA concentrations. There was 
no difference between these patients and the cohort that 
did not meet the criteria for depression. 
 We have also demonstrated that the consequences of the 
elevated AA levels include signifi cant elevations in both 
PGE 2 and LTB 4 in our IBS cohort. Of further interest is that 
the elevation in serum PGE 2 concentrations is largely due to 
the D-IBS subtype, whereas the trend toward elevated LTB 4 
levels is equally apparent across all disease subtypes and sta-
tus. Our laboratory and other research groups have recently 
reported elevated IL-6 levels in IBS ( 11, 26 ). The source of 
such alterations has heretofore not been identifi ed, but it is 
possible that the fi ndings reported here might shed some 
light on the matter. It has previously been reported that 
PGE 2 can elevate IL-6 levels ( 24 ). Furthermore, it has been 
shown that PGE 2 itself can activate COX-2, the inducible 
enzyme responsible for the formation of its immediate, un-
stable precursor prostaglandin H 2 (PGH 2 ) ( 37 ). It is cer-
tainly plausible that the altered biological cascade described 
here could foster the disturbed basal IL-6 profi le reported 
in IBS due to a self-sustaining, but low level, chronic in-
crease in PGE 2 production. Interestingly, although PGE 2 
does possess anti-infl ammatory properties, they do not ap-
pear to extend to IL-6 ( 38 ). 
 Of course, these alterations in PUFA metabolites may 
have additional functional consequences. AA itself has a 
role in intestinal barrier function ( 39 ), and the increases 
described here are likely to have an impact in that regard. 
A role for elevated PGE 2 levels in altered GIT muscle activ-
ity is also possible ( 23 ). Of further note is that circulating 
PGE 2 can readily cross the blood brain barrier and thus 
impact the CNS component of the brain-gut axis, as well as 
the ENS ( 40 ). An increased number of GIT immune cells 
has been proposed as an indicator of immune activation in 
IBS ( 41, 42 ). Interestingly, LTB 4 is regarded as a neutro-
phil chemoattractant and a promoter of both leukocyte 
adhesion and infi ltration ( 22, 43 ). Moreover, the elevated 
LTB 4 we report here may have relevance to the morpho-
logical and functional changes that have been detected in 
mast cells in IBS ( 44 ), as this leukotriene is both an activa-
tion product of mast cells and a chemoattractant for their 
progenitors ( 45 ). It is also known that alterations in basal 
prostaglandin levels can impact on the brain-gut axis 
through the effects they exert on HPA-axis secretory activ-
ity ( 40 ). In short, these eicosanoids and their PUFA pre-
cursor are critical agents in the normal functioning of the 
GIT, and the perturbations in the system we have described 
here could directly or indirectly impact motility, secretion, 
nociception, cytoprotection, and the immunological mi-
lieu of the gut ( 46, 47 ). Moreover, we cannot exclude that 
there are other AA metabolites produced along this com-
plex metabolic cascade that contribute to the physiologi-
cal and behavioral symptoms associated with IBS. 
 Contrary to our expectations, the increases in AA levels 
occurred despite an apparent shift toward the   -3 PUFA 
arm of the metabolic cascade. We found that total   -3 levels 
were signifi cantly elevated in our IBS cohort compared with 
controls without any alteration in total   -6 levels. The factors 
behind this shift toward the   -3 fatty acids are diffi cult to ex-
did not take account of possible gender differences in 
PUFA profi les that have been previously reported ( 35 ). 
 Correlation analyses revealed that there was no relation-
ship between plasma AA concentrations and IBS symptom 
severity, suggesting that elevated AA is not a direct cause of 
IBS. Additionally, if the data is grouped according to those 
with mild, moderate, or severe IBS, the increase is evident 
in all subgroups, albeit at a nonsignifi cant level. Given the 
complexity of AA metabolism ( 23 ), it is not surprising that 
our correlation analysis did not yield a simple linear rela-
tionship between levels of this fatty acid and symptom se-
verity in our IBS patients. It has previously been shown 
that altered fatty acid profi les can have multiple down-
stream effects, confi rming the challenges that confront at-
tempts at correlating elevated AA levels directly with IBS 
symptom scores ( 36 ). Because of the recent association be-
tween AA and depression ( 19 ), we also examined whether 
those patients with a depressive comorbidity made a greater 
 Fig.  3. Serum LTB 4 levels (pg/ml) in healthy female controls 
(n = 19) and female IBS patients (n = 25) ( P < 0.05,  t -test). IBS, irrita-
ble bowel syndrome; LTB 4 , leukotriene B 4 . 
 Fig.  4. Evaluation of the AA levels and IBS symptom severity ac-
cording to the presence or absence of psychiatric comorbidity. 
(4A) AA levels in mild, moderate, and severe IBS. (4B) AA levels in 
IBS patients with and without psychiatric comorbidity. AA, arachi-
donic acid; FAME, fatty acid methyl esters; IBS, irritable bowel syn-
drome; IBS+, IBS with psychiatric comorbidity; IBS  , IBS without 
psychiatric comorbidity. 
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plain from the current dataset and are not in line with reports 
from other disorders that have been associated with elevated 
immune parameters such as depression ( 19 ) and Crohn’s dis-
ease ( 48 ). Of note is that in the latter study, the elevated 
  -6:  -3 ratio was related to specifi c cytokine genotypes. We 
did not record subject dietary habits in this study and conse-
quently cannot rule out an altered dietary consumption of 
fatty acids in the IBS cohort. Despite this limitation, data from 
previous studies suggests that such an alteration would have 
an anti-infl ammatory outcome ( 49 ). It is noteworthy that an 
apparent trend toward a reduction in the   -6:  -3 ratio did 
not reach statistical signifi cance in this study and that the 
magnitude of the   -3 shift described may not be large enough 
to be of immunological importance. It is also interesting that 
the IBS is not thought to be more common in countries with 
traditionally high fi sh consumption rates, like Japan, than in 
Western societies ( 5 ). However more detailed epidemiologi-
cal studies are required to probe the potential associations 
that have been demonstrated for other disorders with an in-
fl ammatory component such as depression and cardiovascu-
lar diseases ( 18, 19 ). The results presented here suggest that 
even if dietary factors come into play, they are insuffi cient to 
counteract the sequalae of events leading to the increased 
input to the AA cascade. While the precise mechanism be-
hind these alterations is unclear at the moment, the activity of 
phospholipase A 2 (PLA 2 ), the enzyme responsible for the re-
lease of arachidonic acid from the cell membranes, may be 
worth investigating in future studies ( 50 ). 
 CONCLUSION 
 We have comprehensively characterized the PUFA pro-
fi le in a female IBS population. Our results indicate that 
AA levels are increased in the clinical setting. We have 
demonstrated a clear and robust increase in pro-infl am-
matory markers downstream of AA in our IBS cohort that 
may have relevance for previously described alterations in 
pro-infl ammatory markers such as IL-6. Although further 
studies are required to elucidate the mechanism behind 
this phenomenon, the alterations described here may 
represent a novel biomarker candidate panel in IBS 
that is especially needed given the current reliance on a 
symptom-based diagnostic scheme.  
 The authors would like to acknowledge Dr. Sandra Barry, Ms. 
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